North Point Portfolio Managers Corp OH Sells 269 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

North Point Portfolio Managers Corp OH decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% in the fourth quarter, Holdings Channel reports. The firm owned 17,037 shares of the biopharmaceutical company’s stock after selling 269 shares during the period. Regeneron Pharmaceuticals accounts for 2.1% of North Point Portfolio Managers Corp OH’s investment portfolio, making the stock its 24th largest holding. North Point Portfolio Managers Corp OH’s holdings in Regeneron Pharmaceuticals were worth $12,136,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after buying an additional 11,499 shares during the period. Swiss National Bank boosted its position in Regeneron Pharmaceuticals by 0.6% during the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company’s stock valued at $316,957,000 after acquiring an additional 3,866 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on REGN. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Evercore ISI decreased their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Oppenheimer decreased their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $675.79 on Monday. The firm’s fifty day moving average is $727.19 and its two-hundred day moving average is $936.01. The firm has a market cap of $74.26 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.